Research programme: antibacterials - Actelion
Alternative Names: AB-1; AB-2; AB-3; Actelion-10; Actelion-11; Actelion-9; Injectable antibacterials - Actelion; Oral antibacterials - ActelionLatest Information Update: 27 Jun 2017
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Nosocomial infections
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (PO)